Brief: Redx Pharma Says Zelasudil Granted FDA Orphan Drug Designation

Redx Pharma

21/08/2023 07:14

Aug 21 (Reuters) - Redx Pharma PLC  REDX.L :
    * ZELASUDIL GRANTED FDA ORPHAN DRUG DESIGNATION
    * ZELASUDIL IS CURRENTLY IN A PHASE 2A CLINICAL STUDY FOR
IPF,
WITH TOPLINE DATA EXPECTED IN Q1 2024.

Source text for Eikon:  ID:nRSU8443Ja 
Further company coverage:  REDX.L 

 ((Reuters.Briefs@thomsonreuters.com;;))